UBS O'Connor »

Halozyme Therapeutics shares owned by UBS O'Connor

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by UBS O'Connor from 13F filings

Historical chart of UBS O'Connor investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by UBS O'Connor consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by UBS O'Connor

Quarter filed Position value Share count Share price at filing
2025-09-30 $21M 18M 1.15

More positions owned by UBS O'Connor

Verona Pha Spons (VRNA)
Mr Cooper Group
NVIDIA Corporation (NVDA)
Snowflake Note1 (Principal)
Spirit Aer Comcl (SPR)
Peloton In Note2 (Principal)
Halozyme T Note0 (Principal)
Alliant Energy Corporation (LNT)
Draftkings Note3 (Principal)
Southern C Note4 (Principal)
Entergy Corporation (ETR)
Southern Company (SO)
Packaging Corporation of America (PKG)
Duke Energ Note4 (Principal)
American W Note3 (Principal)

View all positions for UBS O'Connor

Top funds holding Halozyme Therapeutics

Steelhead Partners
Opti Capital Management
Linden Advisors
Millennium Management
MacKay Shields
DeepCurrents Investment Group
Tenor Capital Management
BlackRock
Lazard Asset Management
M&G
Calamos Advisors
Wellesley Investment Advisors
UBS O'Connor
Jpmorgan Chase & Co
State Street Corporation

View all funds holding Halozyme Therapeutics